Literature DB >> 3123558

Immunoglobulin class and subclass profile of the Ro/SS-A autoantibody response.

T S Lieu1, C B Reimer, R D Sontheimer.   

Abstract

We have developed an enzyme-linked immunosorbent assay (ELISA) for autoantibody to Ro/SS-A antigen (anti-Ro/SS-A) in order to more fully characterize the autoimmune response that occurs to this antigen in patients with subacute cutaneous lupus erythematosus (SCLE). The microtiter plate-immobilized, biochemically purified Ro/SS-A antigen reacted with anti-Ro/SS-A antibody, but not with other closely related specificities (anti-La/SS-B, anti-SM, anti-U1-RNP) or normal sera. The optimal pH of antigen-antibody reaction in this ELISA was 7.2. The binding of sera containing anti-Ro/SS-A was inhibited 80% by preincubation with the same amount of Ro/SS-A antigen used for coating the plate. Although 11 of the 14 (79%) SCLE sera studied had precipitating anti-Ro/SS-A antibody by immunodiffusion, 13 (93%) sera had abnormally elevated IgG, IgA, or IgM ELISA binding levels. A good correlation between IgG anti-Ro/SS-A ELISA binding levels and immunodiffusion titers was observed (r - 0.8588, p less than or equal to 0.001) suggesting that IgG is the major anti-Ro/SS-A antibody class detected by double immunodiffusion, Sera with a combination of high rheumatoid factor levels (latex 3+ or higher) and high anti-Ro/SS-A titers (1:8 or higher in immunodiffusion) tended to give an abnormally high IgM anti-Ro/SS-A ELISA binding levels. After rheumatoid factor activity was removed by absorption with heat-aggregated human IgG, a 50% decrease in IgM anti-Ro/SS-A ELISA binding was noted. On the other hand, absorption of rheumatoid factor-negative sera that contained high IgM anti-Ro/SS-A binding activity did not significantly decrease ELISA binding levels. Prednisone and 6-azathioprine reduced the level of IgG anti-Ro/SS-A autoantibody in sera of treated SCLE patients by 50%. The IgG subclass profile of anti-Ro/SS-A autoantibody was analyzed by using mouse monoclonal antibodies specific for the 4 human IgG subclasses. Of anti-Ro/SS-A positive SCLE sera, 91% had predominantly IgG1 subclass autoantibody. The coexistence of IgM and IgG anti-Ro/SS-A autoantibody and the predominance of the IgG1 subclass is compatible with the possibility that this autoantibody response is under T-cell control. The predominance of IgG1 in the autoimmune response to Ro/SS-A antigen in SCLE patients is consistent with the hypothesis that antibody dependent cell mediated cytotoxicity could be an important immunologic effector mechanism in this disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123558     DOI: 10.1111/1523-1747.ep12462142

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.

Authors:  P Eggleton; F J Ward; S Johnson; M A Khamashta; G R Hughes; V A Hajela; M Michalak; E F Corbett; N A Staines; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies.

Authors:  F W Miller; S A Twitty; T Biswas; P H Plotz
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

3.  Molecular characterization of human Ro/SS-A antigen. Amino terminal sequence of the protein moiety of human Ro/SS-A antigen and immunological activity of a corresponding synthetic peptide.

Authors:  T S Lieu; M M Newkirk; J D Capra; R D Sontheimer
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

4.  IgG4 autoantibodies induce dermal-epidermal separation.

Authors:  Sidonia Mihai; Mircea T Chiriac; Josep E Herrero-González; Margaret Goodall; Roy Jefferis; Caroline O S Savage; Detlef Zillikens; Cassian Sitaru
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.